A citation-based method for searching scientific literature


List of co-cited articles
22 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal, Lars Hansen. Diabetes Care 2015
55
80

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
87
60

Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
C Mathieu, M Herrera Marmolejo, J G González González, L Hansen, H Chen, E Johnsson, R Garcia-Sanchez, N Iqbal. Diabetes Obes Metab 2016
42
60

One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
S Matthaei, N Aggarwal, P Garcia-Hernandez, N Iqbal, H Chen, E Johnsson, A Chin, L Hansen. Diabetes Obes Metab 2016
27
60


Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
David M Williams, Jeffrey W Stephens. Expert Opin Pharmacother 2015
11
40

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
40

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
40

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2017
277
40


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40


Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Dirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo Garcia-Sanchez, Raisa Kurlyandskaya, C David Sjöström, Stephan Jacob,[...]. Diabetes Obes Metab 2018
30
40

Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Noboru Kurinami, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouch, Tomio Jinnouchi, Hideaki Jinnouchi. Diabetes Res Clin Pract 2018
33
40

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Jan W Eriksson, Per Lundkvist, Per-Anders Jansson, Lars Johansson, Mats Kvarnström, Linda Moris, Tasso Miliotis, Gun-Britt Forsberg, Ulf Risérus, Lars Lind,[...]. Diabetologia 2018
132
40

Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Lars Johansson, Paul D Hockings, Eva Johnsson, Nalina Dronamraju, Jill Maaske, Ricardo Garcia-Sanchez, John P H Wilding. Diabetes Obes Metab 2020
11
40

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.
Nathalie C Leite, Gil F Salles, Antonio L E Araujo, Cristiane A Villela-Nogueira, Claudia R L Cardoso. Liver Int 2009
316
40

Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Juan P Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, Jill Maaske, Marcia A Testa, Donald C Simonson, Nalina Dronamraju, Ricardo Garcia-Sanchez, Anne L Peters. Diabetes Obes Metab 2020
3
66

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
Raymond Kwok, Kai Chow Choi, Grace Lai-Hung Wong, Yuying Zhang, Henry Lik-Yuen Chan, Andrea On-Yan Luk, Sally She-Ting Shu, Anthony Wing-Hung Chan, Ming-Wai Yeung, Juliana Chung-Ngor Chan,[...]. Gut 2016
223
40

Sulfonylureas: a new look at old therapy.
Peter M Thulé, Guillermo Umpierrez. Curr Diab Rep 2014
76
40

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
40



Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar,[...]. Diabetes Obes Metab 2018
115
20

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
298
20





A review of gliptins for 2014.
André J Scheen. Expert Opin Pharmacother 2015
74
20


Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
201
20

Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Anthony H Barnett, Bernard Charbonnel, Robert G Moses, Sanjay Kalra. Curr Med Res Opin 2015
11
20

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
L A Leiter, H Teoh, O Mosenzon, A Cahn, B Hirshberg, C A M Stahre, J B L Hoekstra, M Alvarsson, K Im, B M Scirica,[...]. Diabetes Obes Metab 2016
19
20

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
20


Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Paola Fioretto, Bergur V Stefansson, Eva Johnsson, Valerie A Cain, C David Sjöström. Diabetologia 2016
57
20

Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
Rose Anderson, Jennifer Hayes, Jeffrey W Stephens. Expert Opin Drug Metab Toxicol 2016
8
20

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg,[...]. Diabetes Care 2015
101
20

SGLT2 versus DPP4 inhibitors for type 2 diabetes.
André J Scheen. Lancet Diabetes Endocrinol 2013
12
20


Cardiovascular effects of gliptins.
André J Scheen. Nat Rev Cardiol 2013
120
20


Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?
Eberhard Standl, Michael Erbach, Oliver Schnell. Curr Treat Options Cardiovasc Med 2014
27
20

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun. Sci Rep 2017
86
20

SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Huilin Tang, Qi Dai, Weilong Shi, Suodi Zhai, Yiqing Song, Jiali Han. Diabetologia 2017
54
20

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
A J Scheen. Diabetes Obes Metab 2010
195
20

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Gian Paolo Fadini, Stefania Saragoni, Pierluigi Russo, Luca Degli Esposti, Saula Vigili de Kreutzenberg, Mario Melazzini, Angelo Avogaro. Diabetes Obes Metab 2017
13
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.